 |
|
Changes in drug pricing affect pharmaceutical industry revenues, the operations of pharmaceutical benefit management (PBM) companies, the stability of federal programs, and ultimately beneficiary costs. CMS recently released a proposed regulation that makes fundamental changes to a widely used price benchmark in the Medicaid system – Average Manufacturer Price (AMP) – but also includes significant changes to other Medicaid policies such as nominal price and Medicaid rebate collection for physician-administered drugs. Audio conference participants learned about these changes, and what they mean for operating health care businesses, the Medicaid program, and other government health care systems.
The 90-minute, interactive Avalere audio conference provided:
- An overview of the changes to drug pricing outlined in the proposed rule;
- Likely reactions to the federal proposal from major stakeholders; and
- Discussion of the potential impact on pharmacy, pharmaceutical, and PBM communities.
This expert session was also designed to prepare organizations for the submission of comments to CMS by a Feb. 20, 2007, deadline.
 |
Register |
- Lauren Barnes, Director, Avalere Health, former Director of the Payment and Coverage Group at Amgen
- John Coster, RPh, PhD, Vice President of Policy and Programs, National Association of Chain Drug Stores
- Carrie J. Gavora, Policy Consultant, Pharmaceutical Care Management Organization
| Registration Prices : |
 |
| Commercial |
$375 |
| Government |
$250 |
| Avalere Client |
$300 |
| Non-profit |
Special rates apply.* |
| Cancellation Policy: To receive a refund, notice is required at least seven business days prior to the audio conference. With proper notice, fees are refunded minus a $40 service fee. No refunds are given for cancellations received with less than seven days notice. Avalere Health reserves the right to cancel or reschedule an audio conference due to unforeseen circumstances. |
|
